Answers are grounded in this paper and cite their sources.
These findings highlight the translatability between zebrafish and murine models, provide evidence of aberrant RAS-MAPK signaling as an adaptive mechanism of resistance to lorlatinib, and demonstrate the clinical potential for SHP2/ALK inhibitor combinations for the treatment of ALK-mutant neuroblastoma, including those with acquired tolerance or potentially resistance to ALK-TKIs.
No takes yet. Share an insight, caveat, or question.
Valencia-Sama et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: